Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

BACKGROUND: Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity and the fraction of circulating DNA in plasma that is tumor-derived (i.e., cfDNA tumor f...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsui, Dana W. Y., Cheng, Michael L., Shady, Maha, Yang, Julie L., Stephens, Dennis, Won, Helen, Srinivasan, Preethi, Huberman, Kety, Meng, Fanli, Jing, Xiaohong, Patel, Juber, Hasan, Maysun, Johnson, Ian, Gedvilaite, Erika, Houck-Loomis, Brian, Socci, Nicholas D., Selcuklu, S. Duygu, Seshan, Venkatraman E., Zhang, Hongxin, Chakravarty, Debyani, Zehir, Ahmet, Benayed, Ryma, Arcila, Maria, Ladanyi, Marc, Funt, Samuel A., Feldman, Darren R., Li, Bob T., Razavi, Pedram, Rosenberg, Jonathan, Bajorin, Dean, Iyer, Gopa, Abida, Wassim, Scher, Howard I., Rathkopf, Dana, Viale, Agnes, Berger, Michael F., Solit, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165771/
https://www.ncbi.nlm.nih.gov/pubmed/34059130
http://dx.doi.org/10.1186/s13073-021-00898-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165771/
https://www.ncbi.nlm.nih.gov/pubmed/34059130
http://dx.doi.org/10.1186/s13073-021-00898-8

Ejemplares similares